Developing an oxygen-sensing stimulation patch to prevent pressure ulcers
People with limited mobility can develop pressure ulcers when prolonged loading damages tissue and restricts oxygen supply. Nurses rely on skin checks, repositioning and protective surfaces, but early damage can develop before it becomes visible and prevention requires repeated attention.
COMAS Medical is developing a patch intended to protect vulnerable skin by responding to falling tissue oxygen levels. Automated intervention aims to help care teams prevent pressure ulcers and reduce the burden of repeated manual monitoring in high-risk patients.
What stands out about COMAS Medical
COMAS secured SEK 500,000 from Vinnova, a SEK 60,000 VGR planning grant in April 2026, and a Wikström Foundation development donation in May 2025.
COMAS holds an exclusive global licence to Worcester Polytechnic Institute’s transcutaneous oxygen-sensor technology.
COMAS established a joint-development agreement with medical technology company Masimo for oxygen sensors used in its development programme.
In Mawson’s 1993 precursor study, 29 people with spinal cord injury had a 35% rise in sacral oxygen tension after 30 minutes of electrical stimulation.
Sahlgrenska Science Park selected COMAS for its CO-AX incubator and allocated partial project funding of undisclosed amount.
Co-founder Matthew Miskimin founded Osprey Group in 1995, commercialising technology and investing in medical-device ventures.
Co-founder Anthony Mawson earned a Tulane epidemiology doctorate and researched pressure-ulcer risk in spinal cord injury.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.